Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female 18 to 45 years of age.~* If female, is currently not pregnant/breast feeding/ or attempting to become pregnant has a negative serum pregnancy test, or is of non-childbearing potential or is of child-bearing potential, willing to commit to using a consistent and acceptable method of birth control or is of child-bearing potential and not sexually active~* Body mass index (BMI) of 18.5 to 29.9 kg/m² inclusive and a body weight ≥50 kg.~Main Exclusion Criteria:~* FEV1 value less than 80% of the predicted value and FEV1/FVC ratio \<0.7.~* History or current evidence of a clinically significant disease or disorder capable of altering the absorption, metabolism, distribution or elimination of drugs.~* History or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neuropsychological, endocrine, gastrointestinal or pulmonary.~* Presence of glaucoma, cataracts, ocular herpes simplex, malignancy, regardless of the clinical significance or current stability of the disease.~* History or presence of silent infections, including positive tests for HIV1, HIV2, Hepatitis B and Hepatitis C.~* Bacterial or viral infection of the upper respiratory tract (including the common cold and flu), sinus, or middle ear within 2 weeks of dosing.~* Lower respiratory tract infection/pneumonia within the past 3 months.~* Presence of any disease or condition or regular concomitant treatment (including vitamins and herbal products) known to interfere with the absorption, distribution, metabolism or excretion of drugs.~* Screening haemoglobin value of less than 1g/dL above the ULN (or 10g/L)~* History of recurrent vasovagal collapses.~* History of anaphylactic/anaphylactoid reactions.~* History of seizures including febrile seizures excluding childhood febrile convulsions.~* Unable to demonstrate proper inhalation techniques involved in using the delivery devices at screening.~* Exposure to any investigational drug within 90 days of the Screening Visit.~* Known or suspected hypersensitivity or idiosyncratic reaction to any steroid, any β2 agonist,or to lactose monohydrate, leucine or Tween 80.~* History of allergy to milk protein.~* Use of an inhaled corticosteroid within 30 days or systemic corticosteroid within 60 days of the Screening Visit.~* Use of medications or herbal medicines that are strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 30 days prior to Screening Visit~* Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study.~* Use of caffeine containing beverages more than 600 mg of caffeine/day.~* Current smokers or ex-smokers who have stopped smoking for less than 10 years.~* Recent or current (suspected) drug abuse or positive result in the drugs abuse test.~* Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 14 units per week for females \[1 unit = 4 cl spirits or equivalent\]).~* Predictable poor compliance, intolerance to charcoal solution, or inability to communicate well with the study centre personnel or inability to participate in all treatment periods.~* The subject is not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions, has participated in a clinical research study within the previous three months or has previously been enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A-B1-B2-C-D (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- B1-C-A-D-B2 (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- C-D-B1-B2-A (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- D-B2-C-A-B1 (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- B2-A-D-B1-C (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- D-C-B2-B1-A (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- B2-D-A-C-B1 (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- A-B2-B1-D-C (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- B1-A-C-B2-D (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
- C-B1-D-A-B2 (Type: EXPERIMENTAL): Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete